PHARMAIDS PHARMACEUTICALS LTD.

Pharmaids Pharmaceuticals Ltd has filed its Annual Report for the Financial Year 2025-2026 and announced the 37th Annual General Meeting (AGM) scheduled for September 11, 2026. The report and AGM notice have been sent via email to registered members, with a web-link provided to others. The company is offering remote e-voting facilities through CDSL for all AGM business items. Key dates for e-voting include commencement on September 8, 2026, and end on September 10, 2026, with a cut-off date of September 4, 2026. The filing also lists the Board of Directors, key management personnel, auditors, and registrars.

Pharmaids Pharmaceuticals Ltd has issued a notice for its 37th Annual General Meeting (AGM) scheduled for Friday, September 11, 2026, at 12:00 noon IST. The company has also released its Annual Report for the Financial Year 2025-2026. Both documents have been disseminated via email to members with registered email addresses and through a web-link for those without. The company is providing a remote e-voting facility through CDSL for all business items on the AGM agenda. Key dates include a cut-off date of September 4, 2026, with e-voting commencing on September 8 and concluding on September 10, 2026.

Pharmaids Pharmaceuticals Ltd announced the outcome of its Board meeting held on August 12, 2026. The Board approved the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026. A Limited Review Report from statutory auditors M/s PPKG & Co was also enclosed. Additionally, the Board considered and approved the Notice of the 37th Annual General Meeting (AGM), which will be held via Video Conferencing (VC) or Other Audio-Visual Means (OAVM). The meeting commenced at 4:57 PM and concluded at 6:15 PM.

Pharmaids Pharmaceuticals Limited announced that its Board of Directors, in a meeting held on August 12, 2026, approved the unaudited financial results (standalone and consolidated) for the quarter ended June 30, 2026. A Limited Review Report from statutory auditors M/s PPKG & Co. is enclosed. The company also approved the notice for its 37th Annual General Meeting (AGM), which will be conducted via Video Conferencing (VC) or Other Audio-Visual Means (OAVM). Further details and the complete financial results will be published in newspapers with a QR code linking to the company's webpage.

Pharmaids Pharmaceuticals Ltd has announced that its Board of Directors will convene on August 12, 2026. The primary agenda item for this meeting is to consider and approve the Unaudited Financial Results for both standalone and consolidated operations for the quarter ended June 30, 2026. Additionally, the company confirmed that the trading window for its securities, which was closed from July 01, 2026, will reopen 48 hours after the declaration of these financial results. The information will be available on the company's website.

Pharmaids Pharmaceuticals Ltd has appointed M/s. V Mahendra & Associates, Chartered Accountants, as its Internal Auditors for the financial year 2026-27. The decision was approved by the Board of Directors based on the recommendation of the Audit Committee during their meeting held on June 30, 2026. The firm has over 23 years of experience in corporate compliance and financial systems.

Pharmaids Pharmaceuticals Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will be shut from July 01, 2026, until 48 hours after the declaration of the company's unaudited financial results for the quarter ended June 30, 2026. The specific date for the board meeting to consider these financial results will be communicated later. The company will also update its website with this information.

Pharmaids Pharmaceuticals Ltd has announced the resignation of Dr. Jagadeesh M N from his position as Vice President – Discovery Services, a key Senior Management Personnel. The resignation is effective from the closure of business hours on June 25, 2026, and is stated to be for personal reasons. The company has provided the necessary disclosures as per SEBI regulations and made the information available on its website. This change in senior management personnel is a significant event for the company's operational continuity and strategic direction in its discovery services division.

Pharmaids Pharmaceuticals Ltd has issued a corporate guarantee of ₹55,00,000 to State Bank of India on behalf of its unlisted material subsidiary, Adita Bio Sys Private Limited. This guarantee secures a new loan facility for Adita under the Emergency Credit Line Guarantee Scheme (ECLGS) 5.0. The company stated that the promoter/promoter group/group companies have no interest in this transaction, and it is conducted at arm's length. The guarantee represents a contingent liability for Pharmaids Pharmaceuticals Ltd, with no immediate impact on the company's financials as it pertains to a consolidated group entity.

Pharmaids Pharmaceuticals Ltd's Board approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, in a meeting held on May 29, 2026. They also approved a corporate guarantee not exceeding ₹75,00,000 for Adita Bio Sys Private Limited, a material subsidiary, under the Emergency Credit Line Guarantee Scheme (ECLGS) 5.0. The board meeting commenced at 05:02 P.M. and concluded at 05:55 P.M.